Tuesday, October 21, 2025 from 10:15 a.m. to 11:45 a.m. CDT at Greenway FGHIJ, 2nd Floor
This session is being recorded.
Learn MoreAvailable for 1.50 hours of CPE creditActivity Number: 0217-0000-25-117-L01-PActivity Type: An Application-Based ActivitySince the publication of the 2018 guidelines for the management of blood cholesterol, the development of new recommendations and the availability of new therapeutic agents have impacted the management of dyslipidemia. The first session of this program will review current therapy recommendations according to the most recent guidelines, including a review of the evidence suggesting that decreased low-density lipoprotein cholesterol (LDL-C) levels should be targeted for patients at increased risk of cardiovascular events. It will also discuss evidence supporting the use of novel, non-statin therapies and their place in therapy. The second portion of the program will involve a pro-con debate that will review the application of new and existing medications that may have a role in reaching lower LDL-C targets to a series of patient cases.
Learning Objectives1. Summarize updated treatment pathways for lipid management according to the most recent guidelines.
2. Differentiate recommendations for targeting low-density lipoprotein cholesterol (LDL-C) levels for patients at risk for cardiovascular events.
3. Evaluate the role of newer non-statin agents in lipid management.
4. Debate the optimal approach to cardiovascular risk reduction using lipid-lowering therapy.
 | | Moderator: | Ann M. Philbrick, Pharm.D., FCCP, BCACP | | Professor
Department of Pharmaceutical Care and Health Systems & Department of Family Medicine and Community Health
University of Minnesota
Minneapolis, MN | | View Biography |
|
A Moving Target: New Guidelines, New Goals and Novel Agents to Get Us There10:15 a.m. to 10:45 a.m. | | Speaker: | Bruce A. Warden, Pharm.D., CLS, FNLA, FASPC | | Clinical Pharmacist
General Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon
| | View Biography |
|
|
The Great Debate: Selecting Lipid-Lowering Therapy After Maximally Tolerated Statins (Pro)10:45 a.m. to 11:15 a.m. | | Speaker: | Kate Cabral, Pharm.D., FCCP, FACC | | Associate Professor
Albany College of Pharmacy & Health Sciences
Director Metabolic Services
Capital Cardiology Associates
Albany, NY | | View Biography |
|
|
The Great Debate: Selecting Lipid-Lowering Therapy After Maximally Tolerated Statins (Con)11:15 a.m. to 11:45 a.m. | | Speaker: | Kelsey E. Norman, Pharm.D., BCACP, BCCP | | Clinical Coordinator - Ambulatory Care & Scholarship & PGY2 Ambulatory Care Residency Program Director
Boston Medical Center
Boston, MA | | View Biography |
|
|